

Aptorum Group Prospectus Receives Approval for Listing on the Euronext Paris Stock Exchange

NEW YORK--([BUSINESS WIRE](#))-- Regulatory News:

Aptorum Group Limited (Nasdaq:APM) (“**Aptorum Group**”), a biopharmaceutical company focusing on the development of novel therapeutics to address global unmet medical needs, today is pleased to announce that the French *Autorité des Marchés Financiers* (“**AMF**”) has granted visa number 20-352 on its prospectus in respect of its fast path cross-listing of its Class A Ordinary Shares (the “**Shares**”) on the Professional Compartment of Euronext in Paris. The Company did not issue any additional shares. The Shares will be traded under the Euronext ticker symbol “APM” and ISIN code: KYG6096M1069 and is expected to commence trading on 24 July 2020.

Aptorum Group’s cross-listing on Euronext Paris is believed to help to continue to diversify Aptorum Group’s investor base and is expected to enhance Aptorum Group’s market visibility and global recognition, and is aligned with Aptorum Group’s strategy for the European Union.

Mr. Ian Huen, Founder, Chief Executive Officer and Executive Director expressed the following: *“Further to our current listing on Nasdaq, we are delighted to announce our further listing on the Euronext Paris markets. Europe, in addition to the United States, continues to be a key market for our company’s future commercialization or development collaboration plans for our portfolio of therapeutics. The European Union has in excess of 440 million¹ in population and healthcare spending amounts c. 10% of the average GDP per year² and growing. We are confident that the Euronext listing will continue to support the expansion of our footprint, as well as strategically align with our key targeted product markets in the European Union.”*

Reed Smith LLP acts as Aptorum Group’s legal advisor and listing agent. BNP Paribas Securities Services acts as Aptorum Group’s trading agent.

About Aptorum Group

Aptorum Group Limited (Nasdaq:APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group’s current drug pipeline includes indications in orphan diseases, infectious diseases and metabolic diseases, a number of which are targeted to enter clinical trial phases. Aptorum Group is also launching a women’s health supplement, dioscorea opposita bioactive nutraceutical tablets marketed under the brand name NativusWell®.

For more information about the Company, please visit our website: www.aptorumgroup.com.

Disclaimer and Forward-Looking Statements

This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

This announcement is an advertisement and not a prospectus within the meaning of the Regulation (EU) n°2017/1129 of 14 June 2017 as amended by Regulations Delegated (EU) n°2019/980 of 14 March 2019 and n°2019/979 of 14 March 2019.

This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks,

uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company's anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group's Form 20-F and other filings that Aptorum Group may make with the SEC in the future and the prospectus, which received the French *Autorité des Marchés Financiers* visa n°20-352 on 16 July 2020. As a result, the projections included in such forward-looking statements are subject to change and could be materially different from those described herein. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

This press release is provided "as is" without any representation or warranty of any kind. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise.

1
https://europa.eu/european-union/about-eu/figures/living_en#:~:text=The%20EU%20covers%20over%204.population%20

2
<https://ec.europa.eu/eurostat/web/products-eurostat-news/-/DDN-20200331-1#:~:text=On%20average%20in%20the%20>

Contacts

Investor relations

Aptorum Group limited

Investor Relations Department:

+852 3953 7700

investor.relations@aptorumgroup.com

Actifin – Financial Communications Europe

Investor relations

Ghislaine Gasparetto

ggasparetto@actifin.fr

+33 1 56 88 11 22

Redchip – Financial Communications United States

Investor relations

RedChip Companies, Inc.

dave@redchip.com

+1 407 491 4498

Source: Aptorum Group Limited